MyOme secured strategic backing from Illumina to launch a prospective trial (MPH) combining whole‑genome sequencing and AI‑driven polygenic risk scores to evaluate clinical and economic value at a population level. Illumina’s investment—paired with early access to sequencing platforms—will support MyOme’s trial design and commercialization plans for ancestry‑aware risk models. Illumina framed the deal as aligning with its multiomic and population‑health strategy, while MyOme said the study will test whether genomic risk prediction and early interventions can improve outcomes and reduce downstream costs.